DK2173886T3 - Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante - Google Patents

Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante

Info

Publication number
DK2173886T3
DK2173886T3 DK08783201.0T DK08783201T DK2173886T3 DK 2173886 T3 DK2173886 T3 DK 2173886T3 DK 08783201 T DK08783201 T DK 08783201T DK 2173886 T3 DK2173886 T3 DK 2173886T3
Authority
DK
Denmark
Prior art keywords
vlps
plant
particles
influenza virus
hemagglutinin produced
Prior art date
Application number
DK08783201.0T
Other languages
English (en)
Inventor
Pierre-Olivier Lavoie
Nathalie Landry
Aoust Marc-Andre D
Manon Couture
Frederic Ors
Sonia Trepanier
Michele Dargis
Louis-Philippe Vezina
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Application granted granted Critical
Publication of DK2173886T3 publication Critical patent/DK2173886T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Software Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
DK08783201.0T 2007-07-13 2008-07-11 Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante DK2173886T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US95941407P 2007-07-13 2007-07-13
US99060307P 2007-11-27 2007-11-27
US1327207P 2007-12-12 2007-12-12
CA002615372A CA2615372A1 (en) 2007-07-13 2008-01-21 Influenza virus-like particles (vlps) comprising hemagglutinin
US2277508P 2008-01-22 2008-01-22
PCT/CA2008/001281 WO2009009876A1 (en) 2007-07-13 2008-07-11 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant

Publications (1)

Publication Number Publication Date
DK2173886T3 true DK2173886T3 (da) 2013-09-30

Family

ID=40255124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08783201.0T DK2173886T3 (da) 2007-07-13 2008-07-11 Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante

Country Status (19)

Country Link
US (4) US20100239610A1 (da)
EP (1) EP2173886B1 (da)
JP (1) JP5624465B2 (da)
KR (1) KR101541330B1 (da)
CN (1) CN101883856B (da)
AU (1) AU2008278222B2 (da)
CA (2) CA2615372A1 (da)
CR (1) CR11209A (da)
DK (1) DK2173886T3 (da)
EA (1) EA018206B1 (da)
ES (1) ES2428384T3 (da)
MX (1) MX2010000525A (da)
MY (1) MY155236A (da)
NZ (1) NZ582360A (da)
PL (1) PL2173886T3 (da)
PT (1) PT2173886E (da)
SI (1) SI2173886T1 (da)
TN (1) TN2009000557A1 (da)
WO (1) WO2009009876A1 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350854B (en) 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
CA2659275C (en) * 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2610345B1 (en) 2007-11-27 2015-08-19 Medicago Inc. Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
CA2730408A1 (en) * 2008-07-11 2010-01-14 Chin-Fen Yang Influenza hemagglutinin and neuraminidase variants
AU2015202195B2 (en) * 2008-07-18 2017-10-12 Medicago Inc. New influenza virus immunizing epitope
PT2318530T (pt) * 2008-07-18 2016-09-30 Medicago Inc Novo epítopo de imunização contra o vírus da gripe
AU2010225930B2 (en) 2009-03-16 2017-01-12 Dsm Ip Assets B.V. Protein production in microorganisms of the phylum Labyrinthulomycota
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
DK2417153T3 (da) * 2009-04-09 2014-12-01 Alfa Biogene Internat B V Filtrering af en væske, der omfatter et stressprotein fra en plante
US10272148B2 (en) * 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
ES2566361T3 (es) 2009-07-02 2016-04-12 Massachusetts Institute Of Technology Composiciones y métodos para diagnosticar y/o tratar una infección gripal
PT3354657T (pt) * 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
AU2010339544B2 (en) 2009-12-28 2015-11-12 Merial Limited Production of hemagglutinin-neuraminidase protein in microalgae
EP3505632B1 (en) * 2009-12-28 2022-08-03 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
CA2785653C (en) * 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2015202267B2 (en) * 2010-01-26 2017-03-23 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
MX342716B (es) 2010-02-18 2016-10-11 Sinai School Medicine Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
CA2792537A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US8802110B2 (en) 2010-09-21 2014-08-12 Massachusetts Institute Of Technology Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
US20130259928A1 (en) 2010-09-30 2013-10-03 Franvax S.R.L. Generation of virosome particles
US10226527B2 (en) 2010-10-04 2019-03-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2816190C (en) * 2010-10-27 2020-03-24 Philip Morris Products S.A. Methods for capturing virus like particles from plants using expanded bed chromatography
CN103282501A (zh) 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
CN103502455A (zh) * 2011-01-17 2014-01-08 菲利普莫里斯生产公司 用于在植物中核酸表达的载体
TWI620816B (zh) * 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
MX350421B (es) * 2011-06-13 2017-09-06 Medicago Inc Producción de partículas tipo virus de la rabia en plantas.
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
PT2760882T (pt) 2011-09-30 2023-08-07 Medicago Inc Aumento do rendimento de partícula semelhante a vírus em plantas
CA2855252C (en) * 2011-11-11 2023-03-07 Philip Morris Products S.A. Influenza virus-like particles (vlps) comprising hemagglutinin produced in nicotiana tabacum
WO2013119683A1 (en) 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2863949C (en) 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
WO2013142329A1 (en) 2012-03-22 2013-09-26 Fraunhofer Usa, Inc. Virus -like particles comprising a matrix protein from a plant enveloped virus and uses thereof
ES2845698T3 (es) * 2012-05-11 2021-07-27 Medicago Inc Producción de partículas de tipo rotavirus en plantas
KR102134815B1 (ko) * 2012-09-05 2020-07-17 메디카고 인코포레이티드 식물에서 피코르나바이러스-유사 입자 생산
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN112592389A (zh) 2013-03-28 2021-04-02 莫迪卡戈公司 植物中流感样病毒颗粒的产生
JP6358257B2 (ja) 2013-09-06 2018-07-18 三菱ケミカル株式会社 植物を用いたタンパク質の製造方法
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
EP3167057B1 (en) * 2014-07-11 2020-03-25 Medicago Inc. Modifying protein production in plants
ES2826402T3 (es) 2015-01-23 2021-05-18 Medicago Inc Producción de partículas similares a rotavirus en plantas
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
KR101637955B1 (ko) * 2015-05-18 2016-07-08 한국생명공학연구원 범용성 인플루엔자 바이러스 백신 조성물
KR20180088629A (ko) 2015-07-02 2018-08-06 메디카고 인코포레이티드 자스몬산 경로 활성화제
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
EP3814507A4 (en) * 2018-06-27 2022-07-06 Medicago Inc. INFLUENZA VIRUS HEMAGGLUTININ MUTANTS
JP2021528999A (ja) * 2018-07-04 2021-10-28 プロバイオジェン アーゲー エンベロープウイルスの精製方法
EP3938511A4 (en) 2019-03-14 2023-02-08 Mitsubishi Tanabe Pharma Corporation ENDOGENOUS PLANT EXPRESSION ACTIVATOR
JPWO2021002355A1 (da) 2019-07-03 2021-01-07
CN111122417B (zh) * 2020-02-22 2022-06-21 太原理工大学 一种测定含瓦斯煤开闭孔总体积膨胀率的装置及方法
CN117479831A (zh) 2021-06-09 2024-01-30 南特知识产权控股有限责任公司 用于在植物中生产感兴趣的蛋白质的方法和系统
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501263A (ja) 1984-11-29 1987-05-21 スクリツプス　クリニツク　アンド　リサ−チ　フアウンデ−シヨン 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
ATE142883T1 (de) * 1991-03-28 1996-10-15 Rooperol Na Nv Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6020169A (en) 1995-07-20 2000-02-01 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
DE69933677T2 (de) 1998-08-11 2007-08-23 Biosource Technologies, Inc., Vacaville Verfahren zur gewinnung von proteinen aus der interstitiellen flüssigkeit von pflanzen
AU6512299A (en) 1998-10-07 2000-04-26 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US6287570B1 (en) * 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
CN1360634A (zh) 1999-04-29 2002-07-24 辛甄塔有限公司 抗除草剂植物
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2002252978B9 (en) 2001-01-18 2007-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
CN1333370A (zh) * 2001-08-16 2002-01-30 深圳市三方圆信息技术有限公司 抗家禽病毒病的作物及其生产方法
US7226774B2 (en) 2002-02-13 2007-06-05 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
JP5350573B2 (ja) * 2002-03-19 2013-11-27 スティヒティング ディーンスト ランドバウクンディフ オンデルズーク 植物におけるｇｎｔｉｉｉ発現
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
CU23202A1 (es) * 2003-01-31 2007-05-18 Ct Ingenieria Genetica Biotech ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
CN1460718A (zh) * 2003-04-11 2003-12-10 浙江大学 表达传染性支气管炎病毒纤突蛋白的转基因马铃薯生产方法
EP1635772A4 (en) 2003-05-05 2008-02-13 Dow Agrosciences Llc STERILE IMMUNOPROPHYLACTIC AND THERAPEUTIC COMPOSITIONS DERIVED FROM TRANSGENIC VEGETABLE CELLS AND METHODS OF PRODUCTION THEREOF
BRPI0410340A (pt) * 2003-05-05 2006-05-30 Dow Agrosciences Llc vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
JP2007528727A (ja) * 2004-02-27 2007-10-18 ザ　ダウ　ケミカル　カンパニー 植物細胞における高効率ペプチド生産
CN101065145B (zh) 2004-08-13 2010-12-15 印度科学工业研究所 嵌合g蛋白基狂犬疫苗
ES2662118T3 (es) 2005-04-29 2018-04-05 University Of Cape Town Expresión de proteínas virales en las plantas
CN100410378C (zh) 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 编码禽流感血凝素的基因及其植物表达载体和应用
BRPI0613625A2 (pt) 2005-07-19 2011-01-18 Dow Global Technologies Inc vacinas da gripe recombinantes
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
WO2007022425A2 (en) 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
SG2014012868A (en) * 2005-10-18 2014-09-26 Novavax Inc Functional influenza virus like particles (vlps)
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
WO2008060669A2 (en) 2006-04-21 2008-05-22 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
JP2009526526A (ja) 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
RU2499053C2 (ru) 2007-06-15 2013-11-20 Медикаго Инк. Способ синтеза белка с модифицированным профилем n-гликозилирования в растениях
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2190472A2 (en) 2007-08-20 2010-06-02 Fraunhofer USA, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2610345B1 (en) * 2007-11-27 2015-08-19 Medicago Inc. Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin
WO2009083420A1 (en) 2007-12-28 2009-07-09 Unilever Plc Process for recovering aroma from tea
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
KR101956910B1 (ko) 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
PT2318530T (pt) * 2008-07-18 2016-09-30 Medicago Inc Novo epítopo de imunização contra o vírus da gripe
CA2736796A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
WO2010025235A1 (en) 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
US10272148B2 (en) * 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
PT3354657T (pt) 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
EP2536428B1 (en) 2010-02-18 2018-12-05 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CN103282501A (zh) 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
SI2635257T1 (en) 2010-11-05 2018-01-31 Novavax, Inc. Particles as rabies virus glycoproteins
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp

Also Published As

Publication number Publication date
PL2173886T3 (pl) 2013-12-31
AU2008278222B2 (en) 2014-03-06
EP2173886A4 (en) 2010-10-13
US9452210B2 (en) 2016-09-27
JP5624465B2 (ja) 2014-11-12
CA2615372A1 (en) 2009-01-13
CA2693956C (en) 2013-09-24
US9492528B2 (en) 2016-11-15
US20230044454A1 (en) 2023-02-09
TN2009000557A1 (en) 2011-03-31
PT2173886E (pt) 2013-09-03
CA2693956A1 (en) 2009-01-22
AU2008278222A1 (en) 2009-01-22
ES2428384T3 (es) 2013-11-07
JP2010533001A (ja) 2010-10-21
EA201000195A1 (ru) 2010-10-29
US20110293650A1 (en) 2011-12-01
KR20100032920A (ko) 2010-03-26
EP2173886B1 (en) 2013-06-26
MY155236A (en) 2015-09-30
MX2010000525A (es) 2010-04-27
WO2009009876A1 (en) 2009-01-22
CR11209A (es) 2010-03-23
US20130183341A1 (en) 2013-07-18
KR101541330B1 (ko) 2015-08-05
CN101883856B (zh) 2013-10-30
SI2173886T1 (sl) 2013-11-29
CN101883856A (zh) 2010-11-10
NZ582360A (en) 2012-04-27
EA018206B1 (ru) 2013-06-28
US20100239610A1 (en) 2010-09-23
EP2173886A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
DK2173886T3 (da) Influenzaviruslignende partikler (VLPS) omfattende hæmagglutinin produceret i en plante
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
ZA201005917B (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
HRP20180706T1 (hr) Kimerna gripa nalik čestici koja sadrži hemaglutinin
BRPI0716536A2 (pt) produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
BR112012010676A2 (pt) partícula de alta eficiência que compreende um agente de benefício.
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
HK1121687A1 (en) Functional influenza virus like particles (vlps) (vlp)
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
DK2043682T3 (da) Influenzavaccine
ZA200809056B (en) Influenza virus vaccine
AP2013006835A0 (en) Novel vaccines against the A/H1N1 pandemic flu virus
IL230708A (en) Influenza virus-like particles containing megalotinin produced in a plant
HK1243353A1 (zh) 犬流感疫苗
GB0619090D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine